Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Investors in Merck (NYSE:MRK) have seen respectable returns of 48% over the past three years — Oct 18th, 2024

It hasn't been the best quarter for Merck & Co., Inc. (NYSE:MRK) shareholders, since the share price has fallen 13% in that time. But that shouldn't obscure the pleasing returns achieved by shareholders over the last three years. After all, the share price is up a market-beating 35% in tha...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE — Oct 19th, 2024

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall S...

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 — Oct 19th, 2024

– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...

Merck Spooks Investors With A Guidance Cut In The Wake Of Light Diabetes, HPV Shot Sales — Oct 31st, 2024

Merck spooked investors on Thursday with a guidance cut after sales of its diabetes drugs and HPV vaccine lagged third-quarter forecasts. Continue reading View comments...